회사 개요
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology firm that leverages its immunology expertise to target the CD40 Ligand (CD40L) pathway for developing therapies aimed at protecting transplanted organs and preventing rejection while also addressing amyotrophic lateral sclerosis (ALS). The company functions within the healthcare sector, specifically the biotechnology industry, a segment characterized by high research and development costs and reliance on novel therapeutic mechanisms to address unmet medical needs. With a market capitalization of $246.85M and an employee base of 33, Eledon maintains a small-scale operational footprint typical of early-stage clinical biotech entities. The market cap figure of $246.85M indicates that the company is valued as a speculative asset with significant potential for expansion if clinical trials succeed, while the absence of reported annual revenue underscores its status as a pre-commercial entity that has not yet generated substantial sales from its product pipeline.
재무 건전성
Eledon reports a net income of $-45,617,000 for the trailing twelve months, while revenue and EBITDA figures are not available due to the company's current stage of development. The substantial gap between the company's minimal revenue generation and its significant net loss of $-45,617,000 reveals a cost structure dominated by research and development expenditures rather than operating leverage from sales. The company generated free cash flow of $-33,657,876, indicating that its current financial flexibility is constrained by heavy cash burn rates required to advance its clinical programs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the fact that the company has not yet reached profitability or generated sufficient revenue to calculate meaningful margins. On the balance sheet, the company holds $133.34M in cash against $641,000 in debt, resulting in a debt-to-equity ratio of 0.47, which suggests a relatively conservative capital structure with minimal leverage despite the cash outflows. The current ratio stands at 7.40, indicating a strong short-term liquidity position where current assets significantly exceed current liabilities, providing ample buffer to cover immediate obligations. Additionally, the return on equity is -35.8% and the return on assets is -30.0%, metrics that reveal that management has not yet been able to generate positive returns on shareholder capital or total assets, a common characteristic for clinical-stage biotechs investing heavily in future growth.
밸류에이션 평가
The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is calculated at -3.86, implying that the market is pricing in future earnings recovery or loss reduction rather than current profitability. The price-to-book ratio is 1.71, indicating that the market values the company at a premium of 71% over its net asset book value, which often reflects the potential value of its intellectual property and clinical pipeline not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional valuation models relying on sales multiples or enterprise value relative to earnings are not applicable for a company with no revenue or EBITDA. The stock has traded between a 52-week low of $1.35 and a 52-week high of $4.60, meaning the current price sits within this range, reflecting the high volatility typical of small-cap biotechnology stocks. The beta value is 0.84, indicating that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to larger technology or financial sectors.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated consistent commercial revenue to calculate growth rates. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue in a traditional sense, as the business is in a pre-revenue phase where capital allocation is focused on development rather than income expansion. Eledon does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available capital and retained earnings into research and development activities rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on capital markets for funding future growth, with no current income generation to support shareholder returns or operational scaling.